Click here to know more about our subscription packages.
Want to commission a custom market research to suit your needs? We are here to help. Let us know.
As per NAVADHI Market Research, the global pharmaceutical industry will we worth USD 1.57 trillion by 2023.
Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases.
Gilead Sciences registered profit in the fourth quarter from a loss last year, helped by a push in income taxes provision.
Company's 2018 Revenue declined 2.6% to USD 5.8 billion. The results reflected by lower product sales in Europe and in other regions. Chronic hepatitis C virus franchise sales plunged 50.8% due to lower average selling price and lower sales volume of Harvoni and Epclusa across all major markets as a result of increased generic competition and the lower patient engagement.
For the fourth quarter, R&D expenses increased by 69.6% Y-O-Y. This was primarily due to an impairment charge related to in-process R&D for multiple myeloma treating program, up-front collaboration expenses and higher investments to support the growth of Gilead’s business following the acquisition of Kite.
Spanning over 30 pages and 18 exhibits, “Gilead Sciences, Inc. - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Gilead Sciences, Inc.
Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?
If yes, then please use the form given below and we will get in touch with you immediately.
Kindly use your official email address and contact number to ensure speedy response.
View all our market research reports